[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-cancer-survivorship\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-cancer-survivorship":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,48,81,108,137,159],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100595445","metabotyping-of-broccoli-microgreen-in-obese-breast-cancer-survivors-100595445",false,"NCT07032545","Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors","Metabotyping of a Functional Food, Broccoli Microgreen, in Obese Breast Cancer Survivors","Inclusion Criteria:\n\n* Female\n* Had a diagnosis of breast cancer (Stage I-III)\n* 2 to 60 months post-curative treatment (surgery, chemotherapy, and\u002For radiation)\n* BMI \\> 30 kg\u002Fm² (obese classification)\n* Willing to avoid cruciferous vegetables during the study\n* Able to sign an IRB-approved consent form\n\nExclusion Criteria:\n\n* Have any contraindications to the proposed nutrition intervention as identified by their medical provider, their designee, or the study team (e.g., GI conditions, medication requirements, pregnancy, breastfeeding, recent history of an eating disorder).\n* Allergy or intolerance to cruciferous vegetables\n* Currently taking broccoli extract supplements","FEMALE",{"count":18,"type":19},24,"ESTIMATED","INTERVENTIONAL",[22],"NA","Obesity can pose significant challenges to maintaining long-term health in cancer survivors by increasing their risk of cancer coming back. Eating a healthy diet is an important way to help manage weight and improve overall health. Broccoli microgreens (BMG) are young broccoli plants packed with nutrients, and research suggests they may help prevent cancer.\n\nPrevious studies in mice showed that BMG can improve gut health and metabolism, leading to better health outcomes in obese animals. This study will test whether BMG can be a useful addition to the diet of obese breast cancer (BC) survivors who have a higher risk of their cancer returning.\n\n24 obese BC survivors will be invited to eat one serving (one cup, \\~57 gram) of fresh BMG every day for two weeks. This will help understand if people can stick to this diet, how their bodies respond, and whether it affects metabolism and inflammation-two key factors linked to cancer risk. Biological markers such as body fat, glucose and lipids as well as gut bacterial changes will be analyzed to see how BMG affects individual health.\n\nThis study may help create new diet strategies to improve health, reduce cancer risk, and support long-term recovery in cancer patients who are overweight or obese. In the future, this research could help doctors personalize nutrition plans to better support cancer survivors.",[25,26],"Obesity and Overweight","Breast Cancer Survivorship",[28,29,30,31,32,33,34],"breast cancer","broccoli microgreen","obesity","survivorship","gut microbiome","metabolomics","metabotyping","RECRUITING","2025-12-16",{"date":38,"type":39},"2025-12-23","ACTUAL",{"date":41,"type":39},"2025-12-03",{"date":43,"type":19},"2028-12-31",{"name":45,"class":46},"University of Maryland, Baltimore","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":20,"phases":60,"briefSummary":61,"conditions":62,"keywords":63,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":47},"100587218","exercise-to-improve-neurovascular-function-in-breast-cancer-survivors-100587218","NCT06925529","Exercise to Improve Neurovascular Function in Breast Cancer Survivors","Protecting Neurovascular Function In lOng-term Breast caNcer Survivors With ExercisE tRaining - The PIONEER Study","PIONEER","Inclusion Criteria:\n\n* Female\n* Aged 45 - 75 years old at study enrolment\n* Diagnosed with stage 1 - 3 breast cancer 5 - 10 years prior to study enrolment\n* Have received potentially toxic chemotherapy, including:\n\n  * Anthracycline (any dose)\n  * Trastuzumab (Herceptin) in breast-cancer with the HER2 mutation OR\n  * Tyrosine kinase inhibitors (e.g. sunitinib) OR\n  * Left chest radiotherapy\n* ≥ 1 'traditional' CVD risk factor (I.e., Hypertension, dyslipidaemia, diabetes, obesity, smoking or family history of CVD) (Mehta et al., 2023)\n* 'Physically inactive', not meeting Australian physical activity guidelines for adults or regularly participating in structured exercise training (Care, 2024).\n* Eligible for Medicare\n* Willing to provide written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Diagnosed CVD or stage B heart failure\n* Diagnosed neurocognitive or cerebrovascular disease\n* Diagnosed atrial fibrillation or cardiac arrythmia\n* BMI ≤ 18.4 kg∙m2\n* Any other contraindications to exercise testing and training that make participation in this study unsafe, determined through medical screening\n* Unable to speak and understand the English language\n* Contraindication to brain MRI\n* Participating in another clinical research trial where randomized treatment would be unacceptable\n* Oncologic (or other) life expectancy ≤ 12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Principal Investigator) that it is not appropriate for the patient to participate in this trial.","45 Years","75 Years",{"count":59,"type":19},40,[22],"Study Rationale:\n\nBreast cancer survivors are more likely to develop cardiovascular disease (CVD) or neurocognitive disease than age-matched counterparts without a history of cancer diagnosis. Some anti-cancer treatments cause damage to the cells of heart and the walls of blood vessels, which may exacerbate neurovascular dysfunction and cancer-related cognitive impairment (symptoms such as 'chemo-brain'), as well as accelerating the onset of neurocognitive disease. Therefore, effective policies and therapeutic strategies are needed to minimize neurovascular dysfunction and neurocognitive disease in at-risk populations like breast cancer survivors.\n\nRegular exercise training is effective in slowing or preventing the development of CVD. Furthermore, higher fitness levels are associated with lower dementia risk in older adults, which may be due to better neurovascular function. However, whether exercise training incorporated into a Cardio-Oncology Rehabilitation and Exercise (CORE) programme can improve neurovascular function in breast cancer survivors is currently unknown. Therefore, the primary aim of this study will be to determine the effect of a CORE programme on neurovascular function in long-term breast cancer survivors.\n\nStudy Description:\n\nThis study will be a randomised controlled trial to investigate the effect of a CORE programme on neurovascular function in long-term breast cancer survivors.\n\nParticipants will complete a series of baseline assessments, including lifestyle questionnaires, a cognitive function assessment, dual-energy x-ray absorptiometry (DXA), a cardiopulmonary exercise test (CPET), ultrasound assessments of arterial stiffness and vascular function, and brain magnetic resonance imaging (MRI). Furthermore, participants will wear a blood pressure monitor at home for 24 hours, and a physical activity monitor for seven days.\n\nFollowing completion of baseline assessments, participants will be randomised to either the CORE program or a 'usual care' group. The CORE program will include a 6-month exercise training program supervised by an Exercise Physiologist at the Baker Heart and Diabetes Institute. The usual care group will carry on with healthcare from their usual healthcare provider(s) for 6 months.\n\nParticipants will then complete two follow-up study visits following completion of the 6-month intervention period, with identical procedures to the baseline study visits.\n\nStudy Duration:\n\nThis study involves two baseline study visits in month 1, followed by two study visits in month 7. Participants randomised to the CORE program will be asked to attend the Baker Heart and Diabetes Institute on a weekly basis for supervised exercise training sessions. However, the supervised exercise training sessions will be provided by a mix of in-person, video-conferencing and tele-health modes depending on each participants availability and needs.",[26],[64,65,66,67,68,69,70],"Breast Cancer","Survivorship","Neurovascular Function","Cerebral Blood Flow","Cardio-Oncology","Exercise Training","Neurocognitive Function","NOT_YET_RECRUITING","2025-09-30",{"date":74,"type":39},"2025-10-02",{"date":76,"type":19},"2025-11-03",{"date":78,"type":19},"2026-08-29",{"name":80,"class":46},"Baker Heart and Diabetes Institute",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":20,"phases":91,"briefSummary":93,"conditions":94,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100552861","phase-2-patient-priorities-for-survivorship-care-in-older-breast-cancer-survivors-100552861","NCT06478589","Patient Priorities for Survivorship Care in Older Breast Cancer Survivors","Inclusion Criteria:\n\n* able to write and speak English\n* Stage DCIS\u002FI\u002FII\u002FIII breast cancer diagnosis\n* 3 months from active cancer therapy (including first or second-line treatment chemotherapy, radiation and\u002For surgery, or multimodal treatment) up to 10 years since completing treatment\n* ≥3 documented comorbidities by chart review, or taking ≥10 medications, have ≥ 1 hospitalization over the past year, ≥ 2 emergency department visits over the past year, seen by \\> 2 specialists over the past year\n* able to provide consent\n\nExclusion Criteria:\n\n* currently on active cancer therapy (including first or second-line treatment chemotherapy, radiation and\u002For surgery, or multimodal treatment)","65 Years","100 Years",{"count":90,"type":19},120,[92],"PHASE2","The objective of this study is to adapt the Patient Priorities Care (PPC) framework to breast cancer survivorship via a user-centered approach, through an iterative process in which patients and their physicians help to refine and modify the intervention. A second objective is to evaluate the feasibility and effectiveness of the adapted PPC framework in breast cancer survivorship for older adults.",[26],[96,97],"Patient priorities","Survivorship Care","2025-08-06",{"date":100,"type":39},"2025-08-12",{"date":102,"type":39},"2025-01-02",{"date":104,"type":19},"2027-06-01",{"name":106,"class":46},"The University of Texas Health Science Center, Houston",3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":16,"minAge":115,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":119,"phases":4,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":47},"100591143","muscle-oxygen-saturation-and-functional-capacity-in-breast-cancer-survivors-100591143","NCT06976593","Muscle Oxygen Saturation and Functional Capacity in Breast Cancer Survivors","Analysis of Muscle Oxygen Saturation and Functional Variables During Physical Performance Tests in Breast Cancer Survivors","Inclusion Criteria:\n\n* Women aged 30 to 70 years\n* Clinical history of breast cancer treatment (at least 6 months prior)\n* Completed primary cancer treatment\n* Ability to perform physical tests\n* Signed informed consent\n\nExclusion Criteria:\n\n* Recurrence or metastasis\n* Severe cardiopulmonary or musculoskeletal disease\n* Neurological or cognitive limitations\n* Ongoing oncological treatment","30 Years","70 Years",{"count":118,"type":19},30,"OBSERVATIONAL","This cross-sectional observational study aims to assess muscle oxygen saturation (SmO2) in the intercostal, quadriceps, and triceps surae muscles using near-infrared spectroscopy (NIRS) during functional exercise tests in breast cancer survivors. Participants will be grouped based on their previous cancer treatment: hormonal therapy only or hormonal therapy combined with chemotherapy. Functional performance will be evaluated through the 6-Minute Walk Test, 30-Second Sit-to-Stand Test, and a submaximal treadmill test. The study will analyze differences in muscle oxygenation and performance between groups and explore associations with other functional and clinical parameters.",[26,122,123,124,125,126,127],"Muscle Oxygenation","Near-infrared Spectroscopy","Exercise","Quality of Life","Functional Capacity","Hormonal Therapy","2025-05-13",{"date":130,"type":39},"2025-05-16",{"date":132,"type":19},"2025-05-05",{"date":134,"type":19},"2025-05-31",{"name":136,"class":46},"University of Extremadura",{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":144,"maxAge":87,"enrollmentInfo":145,"targetDuration":4,"studyType":20,"phases":147,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":157,"locationsCount":47},"100572162","development-and-validation-of-a-personalized-digital-healthcare-model-for-managing-side-effects-in-breast-cancer-survivors-100572162","NCT06729684","Development and Validation of a Personalized Digital Healthcare Model for Managing Side Effects in Breast Cancer Survivors","Development and Validation of Personalized Digital Healthcare Technology and Service Model for the Management and Recovery of Side Effects of Treatment in Breast Cancer Survivors","Inclusion Criteria:\n\n* Individuals who have undergone surgery for Stage 1-2 breast cancer\n* Individuals who have had a unilateral mastectomy\n* Aged 18 years or older and under 65 years\n* Possessing a smartphone with either an Android or iOS operating system\n* Individuals who voluntarily decide to participate after receiving detailed information about the study and provide written consent\n\nExclusion Criteria:\n\n* Individuals who have undergone mastectomy only and are not receiving chemotherapy, radiation, or hormone therapy\n* Individuals with severe comorbidities (such as underlying diseases, neuromuscular disorders, cognitive or mental impairments, visual disabilities, etc.) that make it difficult to use the application or participate in the exercise intervention\n\nDiscontinuation Criteria\n\n* Individuals who undergo delayed breast reconstruction surgery during the study period\n* Individuals who develop severe complications or experience cancer metastasis or recurrence in other organs during the study period, leading to a change in treatment\n* Occurrence of a major illness unrelated to study participation\n* Failure to comply with the instructions of the study physician\n* Situations where the participant voluntarily withdraws from the study or becomes unable to continue participating","18 Years",{"count":146,"type":19},72,[22],"The ultimate goal of this research and development is to develop personalized digital healthcare technologies and self-management strategies based on self-assessment results and evidence, for breast cancer survivors who require management and recovery from acute and chronic side effects related to various treatments (surgery, chemotherapy, radiation, hormone therapy, etc.). Additionally, the aim is to verify the clinical applicability and establish a service model to address the diverse unmet healthcare needs of breast cancer survivors.",[26,64,150],"Digital Health","2024-12-09",{"date":153,"type":39},"2024-12-11",{"date":155,"type":39},"2024-11-13",{"date":134,"type":19},{"name":158,"class":46},"Samsung Medical Center",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":166,"minAge":144,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":20,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":47},"100552312","to-live-better-after-breast-cancer-treatment-100552312","NCT06471452","To Live Better After Breast Cancer Treatment","To Live Better After Breast Cancer Treatment - a Randomized Pilot Trial of a Supportive and Person-centered Care Intervention in Primary Healthcare","Inclusion Criteria:\n\n* patients with breast cancer at the end of curative treatment\n* able to read and understand Swedish\n* considered being physically, psychologically and cognitively able to participate in the study\n\nExclusion Criteria:\n\n\\-","ALL",{"count":59,"type":19},[22],"The most common cancer among women in Sweden is breast cancer. Advances in treatment have improved survival, but these advances have come at a steep price since most treatments impose substantial morbidity and burden on patients and their families. Furthermore, many survivors from cancer have ongoing poor health and well-being and long-term rehabilitation and support should not be neglected to prevent recurrence and increase survival. There are good reasons to believe that routine collection of relevant patient-reported symptoms facilitates person-centered care where the patient is a participatory member of the team. This study aims to pilot-test a supportive and person-centered care intervention in primary healthcare for six months during the first year after primary treatment for breast cancer, assisted by digital technology and compare it to standard care only. The intervention consists of symptom reporting and management in an app in combination with health dialogues with a study-specific nurse at the Primary healthcare centre.",[26],[172,173,174,175],"Breast cancer","Mhealth","Supportive care","Symptom management","2024-06-18",{"date":178,"type":39},"2024-06-24",{"date":180,"type":39},"2023-10-01",{"date":182,"type":19},"2025-12",{"name":184,"class":46},"Karolinska Institutet"]